Cited by 588Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular DiseasesParaoxonase enzyme and polymorphisms

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

Open access

The STABILITY Investigators·2014·New England Journal of Medicine

DOI 10.1056/nejmoa1315878

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Elevated lipoprotein-associated phospholipase A2 activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels of this enzyme are associated with an increased risk of coronary events. Darapladib is a selective oral inhibitor of lipoprotein-associated phospholipase A2. METHODS: In a double-blind trial, we randomly assigned 15,828 patients with stable coronary heart disease to receive either once-daily darapladib (at a dose of 160 mg) or placebo. The primary end point was a composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included the components of the primary end point as well as major coronary events (death from coronary heart disease, myocardial infarction, or urgent coronary revascularization for myocardial ischemia) and total coronary events (death from coronary heart disease, myocardial infarction, hospitalization for unstable angina, or any coronary revascularization). RESULTS: During a median follow-up period of 3.7 years, the primary end point occurred in 769 of 7924 patients (9.7%) in the darapladib group and 819 of 7904 patients (10.4%) in the placebo group (hazard ratio in the darapladib group, 0.94; 95% confidence interval [CI], 0.85 to 1.03; P=0.20). There were also no significant between-group differences in the rates of the individual components of the primary end point or in all-cause mortality. Darapladib, as compared with placebo, reduced the rate of major coronary events (9.3% vs. 10.3%; hazard ratio, 0.90; 95% CI, 0.82 to 1.00; P=0.045) and total coronary events (14.6% vs. 16.1%; hazard ratio, 0.91; 95% CI, 0.84 to 0.98; P=0.02). CONCLUSIONS: In patients with stable coronary heart disease, darapladib did not significantly reduce the risk of the primary composite end point of cardiovascular death, myocardial infarction, or stroke. (Funded by GlaxoSmithKline; STABILITY ClinicalTrials.gov number, NCT00799903.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1315878

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis
Bhatt, D. L. (2006) · JAMA · doi:10.1001/jama.295.2.180 · Cited by 1,644
Concept of Vulnerable/Unstable Plaque
Finn, A. V., Nakano, M., Narula, J., Kolodgie, F. D., & Virmani, R. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179739 · Cited by 1,193
Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis
Bhatt, D. L., Eagle, K. A., Ohman, E. M., Hirsch, A. T., Goto, S., Mahoney, E. M., Wilson, P. W. F., Alberts, M. J., D’Agostino, R., Liau, C.-S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1322 · Cited by 753
Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry
Steg, P. G., Greenlaw, N., Tardif, J., Tendera, M., Ford, I., Kääb, S., Abergel, H., Fox, K. M., Ferrari, R., & on behalf of the CLARIFY Registry Investigators (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs289 · Cited by 653
Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies
‡ (2010) · The Lancet · doi:10.1016/s0140-6736(10)60319-4 · Cited by 595
Effects of the Direct Lipoprotein-Associated Phospholipase A 2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque
Serruys, P. W. J. C., García‐García, H. M., Buszman, P. E., Erné, P., Verheye, S., Aschermann, M., Duckers, H., Bleie, Ø., Dudek, D., Bøtker, H. E., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.771899 · Cited by 498
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development
Wilensky, R. L., Shi, Y., Mohler, E. R., Hamamdzic, D., Burgert, M. E., Li, J., Postle, A. D., Fenning, R. S., Bollinger, J. G., Hoffman, B. E., et al. (2008) · Nature Medicine · doi:10.1038/nm.1870 · Cited by 389
Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor
Macphee, C. H., Moores, K., Boyd, H., Dhanak, D., Ife, R. J., Leach, C. A., Leake, D. S., Milliner, K. J., Patterson, R. A., Suckling, K. E., et al. (1999) · Biochemical Journal · doi:10.1042/bj3380479 · Cited by 359
Detection of Chronic Kidney Disease in Patients With or at Increased Risk of Cardiovascular Disease
Brosius, F. C., Hostetter, T. H., Kelepouris, E., Mitsnefes, M. M., Moe, S. M., Moore, M. A., Pennathur, S., Smith, G. L., & Wilson, P. W. F. (2006) · Circulation · doi:10.1161/circulationaha.106.177321 · Cited by 325
Lipoprotein-Associated Phospholipase A 2 Protein Expression in the Natural Progression of Human Coronary Atherosclerosis
Kolodgie, F. D., BURKE, A. P., Skorija, K., Ladich, E. R., Kutys, R., Makuria, A. T., & Virmani, R. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000244681.72738.bc · Cited by 307

Flagged first, then by citations

Show all 22 references

Research works printed but not linked: 1

10.1042/0264-6021:3380479 · DOI

Sorted by citations

Items 501–588 of 588

Darapladib Fails to Reduce Cardiovascular Events
Foody, J. M. (2014) · Journal watch · doi:10.1056/nejm-jw.na34138
Effect of intensive statin therapy on coronary intervention outcomes, cardiac markers, vaspin, and adiponectin levels in elderly patients with coronary heart disease
Liang, Y., Guo, J., Zhang, Z., Li, Y., & Zhang, Y. (2016) · Translational Surgery · doi:10.4103/2468-5585.179566
Virtual Histology (VH) for Detecting Necrotic Core (NC)
Scalone, G., Brugaletta, S., & Sabaté, M. (2015) · Springer eBooks · doi:10.1007/978-94-007-7741-5_30-1
Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the
y, P. A., Bayés‐Genís, A., de Isla, L. P., Sanchís, J. M., & Heras, M. (2016)
Replacing Magic Bullets With Beneficial Pleiotropy in Atherosclerosis
Bennett, M. R. (2016) · Circulation Research · doi:10.1161/circresaha.116.309934
Atividade nervosa simpática em pacientes com síndromes isquêmicas miocárdicas instáveis: estudo comparativo com marcadores inflamatórios
Moreira, H. G. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2016.tde-30062016-162800
Associação entre inflamação do tecido adiposo epicárdico e doença arterial coronariana: um estudo clinicopatológico
Farias, D. S. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2016.tde-05122016-163220
Vorhofflimmermanagement nur mit guten ABC-Kenntnissen?
Koch, A. H. (2017) · Der Kardiologe · doi:10.1007/s12181-017-0164-y
Flipping the odds of drug development success through human genomicsPreprint
Hingorani, A. D., Kuan, V., Finan, C., Krüger, F. A., Gaulton, A., Chopade, S., Sofat, R., MacAllister, R. J., Overington, J. P., Hemingway, H., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/170142
The Effect of Cardiovascular Risk Factors on the Coronary Circulation
Valenzuela-García, L. F., Matsuzawa, Y., & Lerman, A. (2017) · Springer eBooks · doi:10.1007/978-1-4471-5245-3_6
NEW DIRECTIONS IN ATHEROSCLEROSIS PHARMACOTHERAPY
Дутова, С. В., Saranchina, Y. V., Kilina, O. Y., Polshcha, N. G., Кулакова, Т. С., & Владимирович, Х. Н. (2017) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2017-6-148-154
Inhibition of Adhesion Molecule Expression in Early Progression of Atherosclerosis in Dyslipidemia Model on Sprague Dawley Rats by Darapladib
Heriansyah, T., Lutfiana, N. C., Sulfia, Y. H., Sholichah, Z., Lestari, R. D., Sargowo, D., & Wihastuti, T. A. (2018) · International Journal of Pharmacology · doi:10.3923/ijp.2018.444.450
1986 American Heart Association Bugher Program Pivotal to Current Management and Research of Heart Disease
Roberts, R. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002222
Inflammation als therapeutisches Target
Mauersberger, C., & Sager, H. B. (2019) · CardioVasc · doi:10.1007/s15027-019-1539-8
Advances in cardiovascular imaging
Rollins, A. M. (2019) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2019.05.001
The value of systematic reading. Retaining and applying current information is vital in developing leadership ability.
Groberg, D. H. (1992) · PubMed
Inflammation and Atherosclerotic Cardiovascular Disease
Toth, P. P. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_14
Kardiovaskuläre Inflammation: Stand von Klinik und Forschung
Nettersheim, F. S., & Baldus, S. E. (2019) · Deutsches Ärzteblatt · doi:10.3238/perskardio.2019.10.04.06
Biomarkers
Quispe, R., Das, T. M., & Michos, E. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-75055-8_2
Molecular Imaging of Atherosclerosis
Osborn, E. A., Albaghdadi, M. S., Libby, P., & Jaffer, F. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816386-3.00086-7
Combination of disease and syndrome in coronary artery disease: prevention and treatment strategies
Yiwen, L., BinYu, L. U. O., Cui, J., Zhu, M., Yue, L., Hao, X., Dazhuo, S., & Keji, C. (2022) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0384
19th Annual Scientific Meeting of the Institute Of Cardiovascular Science And Medicine And The 10th Across the Strait Scientific Conference On Cardiovascular Science
(2015) · Journal of the Hong Kong College of Cardiology · doi:10.55503/2790-6744.1041
Lipidsenkende Mittel
Klose, G., & Schwabe, U. (2019) · Springer eBooks · doi:10.1007/978-3-662-59046-1_33
Lipidsenkende Mittel
Klose, G., & Schwabe, U. (2018) · Springer eBooks · doi:10.1007/978-3-662-57386-0_32
Twentieth Anniversary Scientific Meeting
(2016) · Journal of the Hong Kong College of Cardiology · doi:10.55503/2790-6744.1024
Virtual Histology (VH) for Detecting Necrotic Core (NC)
Scalone, G., Brugaletta, S., & Sabaté, M. (2016) · Springer eBooks · doi:10.1007/978-94-007-7678-4_30
Lipidsenkende Mittel
Klose, G., & Schwabe, U. (2016) · Springer eBooks · doi:10.1007/978-3-662-50351-5_32
Lipidsenkende Mittel
Klose, G., & Schwabe, U. (2014) · Springer eBooks · doi:10.1007/978-3-662-43487-1_30
Lipidsenkende Mittel
Klose, G., & Schwabe, U. (2017) · Springer eBooks · doi:10.1007/978-3-662-54630-7_32
The Effect of Darapladib Therapy for the Expression of Lp-PLA2 in Dyslipidemia and Type 2 Diabetes Mellitus Atherosclerosis Model
(2018) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2018.8409
CORONARY ARTERY DISEASE INFLAMMATORY PATHWAYS AND INTERVENTIONS
Silvis, M. J. M. (2022) · doi:10.33540/954
Serum Level of Lipoprotein-Associated Phospholipase A2 and Coronary Artery Disease
Amer, A. S. A., Al-Sheikh, E. H. I., Fouda, M. H., & Elhefnawy, S. B. (2022) · Journal of Advances in Medicine and Medical Research · doi:10.9734/jammr/2022/v34i244914
Inhibición de enzimas fosfolipasas A2 de venenos totales de serpientes como estrategia en la búsqueda de nuevos fármacos
Barrera-Luna, G., & Cazar, M. E. (2023) · Revista CON-CIENCIA · doi:10.53287/khqe6113xv45x
Identification of potential inhibitor(s) against phospholipase A2 using a network pharmacology-based approach
Rajalakshmi, M., Vijayalakshmi, P., & Indu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95699-4.00009-8
Role of platelet-activating factor acetylhydrolase on the inflammatory and apoptotic processes in atherosclerosis
Benı́tez, S., Puig, N., & Sánchez‐Quesada, J. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95698-7.00013-9
Phospholipase activities in cardiovascular disease and its role as a potential biomarker in heart failure
Soumya, R. S., & Ayyappan, P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-21800-2.00016-6
Phospholipase A2 in cardiovascular disease
Pingle, T., & Gupta, G. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-21800-2.00019-1
Additional file 2 of Mendelian randomization analysis of 37 clinical factors and coronary artery disease in East Asian and European populations
Wang, K., Shi, X., Zhu, Z., Hao, X., Chen, L., Cheng, S., Foo, R., & Wang, C. (2022) · Figshare · doi:10.6084/m9.figshare.20064874
Role of Lipoprotein-Associated Phospholipase A2 in Vascular Disease
Rosenson, R. S., & Stafforini, D. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00013-x
Special Patient Populations
Schwartz, G. G., & Do, R. Q. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00039-6
Agreement between mega-trials and smaller trials: a meta-research studyPreprint
Kastrati, L., Raeisi‐Dehkordi, H., Llanaj, E., Quezada‐Pinedo, H. G., Khatami, F., Ahanchi, N. S., Llane, A., Meçani, R., Muka, T., & Ioannidis, J. P. A. (2024) · medRxiv · doi:10.1101/2024.05.09.24307122
Unraveling Novel Therapeutic Targets for Coronary Artery Disease Via Gene Signatures of Plasma Proteome: a Mendelian Randomization Study
Lin, S., Shang, H., & Hassanieh, I. (2024) · Cardiology Research and Cardiovascular Medicine · doi:10.29011/2575-7083.100248
Emerging Cardiovascular Risk Factors
Demeter, S. H., Papp, P., & Weidner, C. (2024) · Springer eBooks · doi:10.1007/978-3-031-53705-9_8
Anti-inflammatory Therapy and Pleiotropic Effects of Drugs in the Treatment of Cardiovascular Diseases Due to Environmental Factors
Mendoza‐Marí, Y., Wilson, V. E. D., Wilson, D. R., & Agrawal, D. K. (2024) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-62806-1_23
Lipoprotein-associated phospholipase A2 and diabetic peripheral neuropathy
Anastasiou, G., Maggio, V., Rizzo, M., & Liberopoulos, E. N. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109020
Advances in Anti-inflammatory Therapies for Cardiovascular Disease and Atherosclerosis
Noman, A. A., Sejuti, S. R., Anuva, N. J., Nabin, M. N. R., Noman, M. J. I., Islam, M. H., Rahman, A., Tanme, T. A., Afrose, F., Hosen, M. N., et al. (2025) · Current Signal Transduction Therapy · doi:10.2174/0115743624366056250407071501
Towards a Mechanistic Understanding of Atherosclerosis Drug Design
Kalantri, S., Thakkar, A. P., Vora, A., & Alavala, R. R. (2025) · Springer eBooks · doi:10.1007/978-981-96-4154-3_22
Atherosclerosis progression under the influence of subclinical inflammation
Tůmová, E. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.045
Statistical Null Hypothesis Testing
Chang, P. C. (2025) · Springer eBooks · doi:10.1007/978-3-031-49984-5_11
95% Confidence Interval
Chang, P. C. (2025) · Springer eBooks · doi:10.1007/978-3-031-49984-5_12
Unpaired Qualitative Data Sets
Chang, P. C. (2025) · Springer eBooks · doi:10.1007/978-3-031-49984-5_6
A narrative review of drugs targeting inflammation in vascular disease
Kristan, J., Malesker, M. A., Backes, J. M., & Hilleman, D. E. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2571944
Elevated protein levels and mRNA upregulation of Lp-PLA2, IL-6, and TNF-α in cardiovascular disease among a Saudi population
Al‐Oanzi, Z. H., Alenazy, F. O., Alhashash, Z. A., Alshammari, R. A., Alruwaili, F. M., Alruwaili, A. H., Alruwaili, A. S., Al-Shammri, F. N., Alfuhaigi, S. H., Alrwily, H. M., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1774428
Additional file 2 of Safety and efficacy of anti-inflammatory therapy in patients with coronary artery disease: a systematic review and meta-analysis
Niu, Y., Bai, N., Ma, Y., Zhong, P.-Y., Shang, Y.-S., & Wang, Z.-L. (2022) · Figshare · doi:10.6084/m9.figshare.19311910
Additional file 3 of Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease
Mourouzis, K., Siasos, G., Oikonomou, E., Zaromitidou, M., Tsigkou, V., Antonopoulos, A., Bletsa, E., Stampouloglou, P. K., Vlasis, K. G., Vavuranakis, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14033687
Additional file 1 of Mendelian randomization analysis of 37 clinical factors and coronary artery disease in East Asian and European populations
Wang, K., Shi, X., Zhu, Z., Hao, X., Chen, L., Cheng, S., Foo, R., & Wang, C. (2022) · Figshare · doi:10.6084/m9.figshare.20064871
Additional file 1 of Lipoprotein-associated phospholipase A2 predicts cardiovascular death in patients on maintenance hemodialysis: a 7-year prospective cohort study
Lin, L., Teng, J., Shi, Y., Xie, Q., Shen, B., Xiang, F., Cao, X., Ding, X., Xu, X., & Zhang, Z. (2024) · Figshare · doi:10.6084/m9.figshare.24993738
Additional file 2 of Lipoprotein-associated phospholipase A2 predicts cardiovascular death in patients on maintenance hemodialysis: a 7-year prospective cohort study
Lin, L., Teng, J., Shi, Y., Xie, Q., Shen, B., Xiang, F., Cao, X., Ding, X., Xu, X., & Zhang, Z. (2024) · Figshare · doi:10.6084/m9.figshare.24993815
Additional file 1 of Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease
Mourouzis, K., Siasos, G., Oikonomou, E., Zaromitidou, M., Tsigkou, V., Antonopoulos, A., Bletsa, E., Stampouloglou, P. K., Vlasis, K. G., Vavuranakis, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14033681
Additional file 3 of Mendelian randomization analysis of 37 clinical factors and coronary artery disease in East Asian and European populations
Wang, K., Shi, X., Zhu, Z., Hao, X., Chen, L., Cheng, S., Foo, R., & Wang, C. (2022) · Figshare · doi:10.6084/m9.figshare.20064880
Additional file 4 of Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease
Mourouzis, K., Siasos, G., Oikonomou, E., Zaromitidou, M., Tsigkou, V., Antonopoulos, A., Bletsa, E., Stampouloglou, P. K., Vlasis, K. G., Vavuranakis, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14033690
Additional file 1 of Safety and efficacy of anti-inflammatory therapy in patients with coronary artery disease: a systematic review and meta-analysis
Niu, Y., Bai, N., Ma, Y., Zhong, P.-Y., Shang, Y.-S., & Wang, Z.-L. (2022) · Figshare · doi:10.6084/m9.figshare.19311907
Additional file 2 of Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease
Mourouzis, K., Siasos, G., Oikonomou, E., Zaromitidou, M., Tsigkou, V., Antonopoulos, A., Bletsa, E., Stampouloglou, P. K., Vlasis, K. G., Vavuranakis, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14033684
Drug Repurposing: Exploring Newer Therapeutic Potentials
Kumbhar, P., Kolekar, K. A., Kamble, V., Porwal, O., Kumbhar, P., Vishwas, S., Disouza, J., Gupta, G., Muhammed, R. A., Gupta, S., et al. (2026) · Springer eBooks · doi:10.1007/978-981-95-4522-3_2
Lp-PLA2 Activity and Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack
Lin, J., Zhou, H., Wang, Y., Jin, A., 李尚志, Zhang, L. J., Meng, X., Xie, X., Jing, J., Jiang, Y., et al. (2026) · Stroke · doi:10.1161/strokeaha.125.052954
Targeting Vascular Inflammation In Patients with Community-Acquired Pneumonia (TIN-CAP): protocol for a multicentre, randomised, double-blind, placebo-controlled trial
Stotts, C., Corrales‐Medina, V., deKemp, R. A., Wells, G. A., Beanlands, R. S., Raggi, P., Ferrara, G., Sligl, W., Connelly, K. A., Paul, N. S., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-114239
Divergent effects of PLA2G7 on prostate cancer biochemical recurrence in European American and African American men
Paller, C. J., Wei, S., Schumacher, M., Rabizadeh, D., Hsu, Y.-C., Lu, C., Chen, Y., Jing, Y., Trock, B. J., Kanayama, M., et al. (2026) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djag036
Nouveaux variants d'épissage de l'Adenylyl cyclase 8 : de la caractérisation fonctionnelle vers la cible thérapeutique
Legueux-Cajgfinger, Y. (2021) · doi:10.70675/d65c888bz60b4z411bz880ezadcfa9488565
Phospholipase A2 Isoforms in Lung Immunity and Respiratory Infections: Potential Targets for Next-Generation Therapy
Joshi, S., Walter, K., Hamiel, D., Saxena, D., & Zheng, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114740
Lysophosphatidylcholine and lysophosphatidic acid as key messengers in atherosclerosis: from a lipid-inflammation vicious cycle to therapeutic translation
Guan, X., Li, Z., Cheng, H., Li, J., Wen, N., & Wang, L. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1875638
Association between lipoprotein-associated phospholipase A2 levels and risk of recurrent cerebrovascular events in patients with ischemic stroke: A systematic review and meta-analysis
Zhang, X., Li, J., Xu, Q., & Xing, G. (2026) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2026.108724
Biography as the Missing Variable in Drug Development: A Case for Bio‐Biographical Mechanistic Profiling
Horwitz, R. I. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70429
PLA2G7-Mediated Pro-Inflammatory Activation of Lipid-Associated Macrophages Drives Pulpitis.
Chen, X.-Y., Huang, X., Lian, C.-X., Zhang, Y.-L., Wu, W.-Z., & Chen, Z. (2026) · International Endodontic Journal · doi:10.1111/iej.70264
Cancer Outcomes in Cardiovascular Trials of Inflammation-Targeting Therapeutics
Yousif, L. I. E., Meijers, W. C., & de Boer, R. A. (2026) · JACC CardioOncology · doi:10.1016/j.jaccao.2026.07.011
Taming inflammation in coronary artery disease: lessons learned, translational breakthroughs, and future directions
Yu, M., Sun, M.-Y., Yang, F., Yuan, Y.-F., Zhang, Y.-M., Ruan, C.-C., 季永, Libby, P., & Cheng, X. (2026) · 中国科学通报：英文版 · doi:10.1016/j.scib.2026.09.081
Making Inflammation Measurable: hsCRP in Cardiovascular Risk Assessment – A Practical Framework for Canadian Care
Dennis, F., Higgins, C. P. B., Madan, M., Fordyce, C. B., Welsh, R., Howlett, J. G., Goodman, S. G., Chua, G. L., Ducharme, A., Bouabdallaoui, N., et al. (2026) · CJC Open · doi:10.1016/j.cjco.2026.10.002
Enzyme−Targeted Therapeutics for Neurological Disorders
Massignan, L., Lokesh, K., Ziadat, S., Uehling, D., Weaver, D. F., & Reed, M. A. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01274
Integrative omics in translational pharmacology: A target‐credibility framework for biomarker‐guided therapy
Altahla, R., Wang, Z., Rong, S., Li, C., Jadgal, N., Mehran, M. J., Bolideei, M., & Alshorman, J. (2026) · Clinical and Translational Discovery · doi:10.1002/ctd2.70223
Repurposing the phospholipase A2 inhibitor, darapladib, to combat multidrug-resistant fungal pathogens, including Candida auris
Elgammal, Y., Salama, E. A., Alkashef, N. M., Lawrence, C. B., & Seleem, M. N. (2026) · PLoS ONE · doi:10.1371/journal.pone.0361366
BindingDB Entry 50002168: Regioselectivity of thiouracil alkylation: Application to optimization of Darapladib synthesis.
BindingDB (2020) · UC San Diego · doi:10.7270/q2gb26n5
BindingDB Entry 50046814: Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.
BindingDB (2016) · UC San Diego · doi:10.7270/q2vq34h4
BindingDB Entry 50000334: Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.
BindingDB (2019) · UC San Diego · doi:10.7270/q2959m00
BindingDB Entry 50047755: Structural and Thermodynamic Characterization of Protein-Ligand Interactions Formed between Lipoprotein-Associated Phospholipase A2 and Inhibitors.
BindingDB (2017) · UC San Diego · doi:10.7270/q23f4rmq
BindingDB Entry 50047361: Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema.
BindingDB (2017) · UC San Diego · doi:10.7270/q2r49sn8
BindingDB Entry 50047671: Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.
BindingDB (2017) · UC San Diego · doi:10.7270/q2z60r0g
BindingDB Entry 50048134: Investigation of a Bicyclo[1.1.1]pentane as a Phenyl Replacement within an LpPLA
BindingDB (2018) · UC San Diego · doi:10.7270/q2862jfc
BindingDB Entry 50047932: Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA
BindingDB (2018) · UC San Diego · doi:10.7270/q27946nd
PET/CT Imaging of Inflammation and Calcification
Emami, H., & Tawakol, A. A. (2014) · Springer eBooks · doi:10.1007/978-3-319-09268-3_15

Authors: The STABILITY Investigators
Affiliations: University of Auckland (NZ)
Corresponding author: The STABILITY Investigators
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2014-05
Volume: 370
Issue: 18
Pages: 1702-1711
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1315878
OpenAlex: W1572528121
Cited by: 579
References: 22
Citations by year: 2026: 23 · 2025: 34 · 2024: 33 · 2023: 27 · 2022: 47 · 2021: 38 · 2020: 34 · 2019: 36 · 2018: 48 · 2017: 63 · 2016: 71 · 2015: 85 · 2014: 37
FWCI: 85.88
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
RECERCAT (Consorci de Serveis Universitaris de Catalunya) (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Spiral (Imperial College London) (submittedVersion)
UEA Digital Repository (University of East Anglia) (submittedVersion)
Funders: Uppsala Universitet
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords: darapladib, lipoprotein-associated phospholipase A2, stable coronary artery disease, cardiovascular events, myocardial infarction, stroke, cardiovascular mortality, major coronary events, all-cause mortality, atherosclerotic plaque vulnerability, lipid-lowering therapy, unstable angina
MeSH terms: Aged, Benzaldehydes, Biphenyl Compounds, Coronary Artery Disease, Coronary Disease, Diethylamines, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Oximes, Pyrimidinones, Sulfides, Treatment Failure, Stroke, Kaplan-Meier Estimate, Phospholipase A2 Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks